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insured urban population in China. Methods: A pooled cross-sectional analy-
sis was performed using China Health Insurance Research Association Database 
of year 2010, 2011 and 2012. Hospitalizations with T2D were identified using 
ICD-10 codes. Adult patients without any cancer or ketoacidosis were included. 
Descriptive statistics were used to analyze hospitalization costs and medication 
usage in T2D patients by age group cut at 60. Results: A total of 11,157 T2D hos-
pitalization records from 13 cities were analyzed, with 56.77% are elderly patients, 
and 32% of total patients have at least one comorbidity. The mean length of stay 
(LOS) per admission was 16 days in elderly patients, and 14 days in patients under 
60. The average direct cost per hospitalization and reimbursement ratio in elderly 
patients were ¥9,036.74 (±7675.74) and 77.34%, compared to ¥8084.34 (±5304.76) 
and 72.11% in patients under 60, respectively. On average, LOS was found 1 day 
longer, and hospitalization costs were found ¥1120 higher in T2D patients with 
comorbidities compared to those without. The average number of medications 
used per admission was 13 and 11 in patients ≧ 60 and under 60, respectively. 
In T2D elderly patients, majority (68.92%) used combination of oral antidiabetic 
drugs (OAD) and insulin. Acarbose and metformin were the most 2 frequently 
used OAD in all treatment choices. For non-antidiabetic medications, the most 
two frequently used drugs were aspirin and mecobalamine. ConClusions: Direct 
medical cost is considerable in elderly T2D patients under hospitalization, espe-
cially in those with comorbidities. The study also showed a complex medication 
usage pattern in elderly population.
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objeCtives: Chronic Kidney Disease (CKD) is a common comorbidity of Type 
2 Diabetes (T2D). This study is to explore the direct cost and medication usage 
pattern in T2D with CKD inpatients among insured urban population in Beijing 
and Tianjin, China. Methods: A pooled cross-sectional analysis was performed 
using hospitalization records in Beijing and Tianjin from China Health Insurance 
Research Association Database of year 2010, 2011 and 2012. Hospitalizations with 
T2D and CKD were identified using ICD-10 codes. Adult patients without any 
cancer or ketoacidosis were included. Descriptive statistics were used to analyze 
hospitalization costs and medication usage. Results: A total of 810 T2D with 
CKD hospitalizations were identified, accounting for 20.1% of the total T2D hospi-
talizations. The mean age (±SD) showed on the records were 62.42 (±11.78) years, 
with 16.15±8.92 days length of stay. The direct cost per admission was 10,155.68 
(±7,614.79), with 77.5% reimbursed by basic medical insurance. Medication cost 
accounted for 47.55% of the total cost, among which 29.57% were antidiabet-
ics. Averaged 15+ drugs were prescribed per admission. For T2D treatment 
choices, 13.33% patients used oral antidiabetic drugs (OAD) alone, and 66.75% 
used OAD and insulin combination. Acarbose and metformin were the two most 
frequently used OADs in all treatment choices. For non-T2D related medication 
treatment in T2D with CKD patients, aspirin and nifedipine were the two most 
frequently used drugs. Drugs on renin-angiotensin system (RAS) were the 5thfre-
quently used non-antidiabetics. ConClusions: Managing T2D among patients 
with CKD could be challenging given the renal impairment. This study showed 
that the direct cost in T2D patients with CKD per hospitalization was consid-
erable and their medicine usage pattern was complex in Beijing and Tianjin in 
China. More attention should be paid to the rational use of medication in such 
population.
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objeCtives: To quantify the association between weight change, diabetes-
related healthcare costs, and HbA1c among patients with type 2 diabetes (T2D); 
analyses were also conducted in sub-group of obese patients with no prior car-
diovascular disease. Methods: This retrospective, observational cohort study 
used U.S. insurance claims linked to laboratory and electronic medical records. 
Study included patients with T2D who were age≥ 18 years and added/switched to 
a non-metformin antidiabetes medication after metformin monotherapy between 
Jan-1-2007-Jun-30-2012 (add/switch date= index). Primary predictor was percent-
age weight change (PWC) between weight measurement at index and follow-up 
measurement 6 months thereafter ranging from negative (loss) to positive (gain). 
Outcomes, measured in 12-month period beginning at follow-up weight meas-
urement, included HbA1c< 7 and diabetes-related healthcare costs. Multivariable 
models quantified the association between PWC (linear effect) and study out-
comes. Results: Primary analysis included 1,520 patients (mean age 55 years; 
47% female); sub-group analysis included 780 patients (mean age 53 years; 51% 
female). Mean (SD) index weight and PWC were 224.6 (52.8) lbs and +0.2% (4.7%) in 
primary analysis; 241.3 (47.3) lbs and -0.2% (4.6%) in sub-group analysis. Negative 
PWC values were significantly associated with higher adjusted probabilities of 
achieving HbA1c< 7 (primary analysis: 58.8 % for PWC of -5% vs. 46.7% for PWC 
of +5%, P< 0.001; sub-group 63.2% for PWC -5% vs. 41.7% for PWC .5%, P< 0.001). 
Increasing PWC was significantly associated with increasing diabetes-specific 
pharmacy costs (P< 0.001) in primary analysis sample and with increasing all-
cause pharmacy costs (P= 0.018), diabetes-specific total costs (P= 0.039), diabetes-
specific medical costs (P= 0.002), and diabetes-specific pharmacy costs (P< 0.001) 
in sub-group sample. PWC was not significantly associated with all-cause total 
was used to estimate the cost of treating T2DM patients to two composite endpoints 
in a UK setting, using 208 week data from a previously published double-blind 
randomised clinical trial of dapagliflozin (DAPA) vs glipizide (GLIP) (NCT00660907). 
Calculation of costs included drug acquisition costs, cost for adverse events, micro- 
and macrovascular complications, and BMI related costs The cost of treating one 
patient to the composite endpoints using DAPA+MET versus GLIP+MET over 208 
weeks was calculated as total cost per treatment arm divided by number of patients 
that reached the composite endpoint in each arm. Results: The number needed 
to treat was 4 for DAPA+MET and 35 for GLIP+MET and overall cost of treating 
one patient over 208 weeks to composite endpoint (1) was £12,042 for DAPA+MET 
and £50,040 for GLIP+MET. The corresponding figures for composite endpoint (2) 
was 4 for DAPA+MET and 47 for GLIP+MET with corresponding costs of £12,666 
and £59,366. ConClusions: The cost of treating one patient to the composite 
endpoints was approximately 4.1-4.7 times higher with GLIP+MET compared to 
DAPA+MET. These results demonstrate that when multiple treatment goals, 
including weight loss and reduction of hypoglycaemic events are targeted, the cost 
of treating patients with DAPA+MET is lower compared to GLIP+MET.
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objeCtives: To correlate spending on diabetes drug prescriptions in English gen-
eral practices with occurrence of risks associated with type 2 diabetes. Methods: 
Data from the HSCIC showing number of prescriptions, by drug, issued in English 
general practices in 2014 and the associated net ingredient cost (NIC) were ana-
lysed using a proprietary in-house software. The total number of patients per CCG 
with diagnosed diabetes, stroke and ischemia, peripheral atrial disease, hyper-
tension, heart failure, coronary heart disease and atrial fibrillation between April 
2013 and March 2014 were identified through the HSCIC’s QOF data. The median 
age in a CCG was identified using ONS 2012 data. Spearman’s correlations and 
partial correlations were performed using SPSS v22.0. ‘Spend’ was defined as 
total NIC. Results: As expected, spending on prescriptions for diabetes drugs 
correlated almost perfectly with the number of diabetes patients (r= 0.97***). All 
the included risks associated with diabetes, bar age, correlated significantly with 
spending on diabetes prescriptions. The highest correlation was with the number 
of patients with obesity (r= 0.92***). The most expensive type of diabetes drugs were 
insulins. The correlations between spend on insulin prescriptions and number 
of patients with each individual diabetes risk was always higher than the cor-
relations between spend on prescriptions for all diabetes drugs and number of 
patients with each individual associated risk. The same was true when correlating 
the total number of prescriptions with occurrence of diabetes associated risks. 
Interestingly, both of these trends remained true when controlling for number of 
patients diagnosed with diabetes using partial correlations. ConClusions: As 
the occurrence of risks associated with diabetes increase, the spend on diabetes 
prescriptions is likely to increase. This is not only because more prescriptions 
are issued but also because the likelihood of insulins, the most expensive type of 
diabetes drugs, being prescribed increases.
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objeCtives: To examine the longitudinal effects and key costs of medication non 
adherence in patients with diabetes mellitus. Methods: The prospective study 
was conducted over a period of six months in a South Indian Village. Adherence to 
treatment has been assessed during a personal interview with each patient by using 
questionnaire. Medication adherence was assessed by using Morisky medication 
adherence scale (MMAS). Results: A total of 658 patients were diagnosed with 
Type 2 diabetes mellitus among them 87% (n= 572) of the patients were prescribed 
with oral hypoglycemic agents for more than a year were selected as study popula-
tion. The statistical significant association with socio demographic and adherence 
rate to antidiabetic therapy indicated that higher prevalence of adherence among 
uneducated (41.22%) elderly (32.82%) women (42.26%) unemployed (29.95%). The 
most common causes for nonadherence to taking medications were lack of knowl-
edge (35.25%) unaffordability () experience of untoward reactions (15.62%). Feeling 
better (26.5%). The adherence levels were 35 %( poor adherence), 27% (medium), 
and 38% (high). Among the poor adherence, 24 patients were hospitalized due to 
diabetic complications like, diabetic foot ulcer (n= 13), diabetic ketoacidosis (07), 
diabetic nephropathy (01), diabetic retinopathy (03). 5 patients were admitted due 
to diabetes induced renal failure. ConClusions: In conclusion, our study revealed 
that poor adherence leads hospitalization and increases the economic burden of 
diabetic patient. By conducting diabetes awareness camps and continued medica-
tion education programme through diabetic centers in village setup can significantly 
reduces the non adherences.
PDB46
Direct cost anD MeDication Usage in elDerly tyPe 2 DiaBetic 
Patients UnDer hosPitalization aMong insUreD UrBan PoPUlation  
in china
Liu Q1, Liu M1, Zhang J2, Chu Y3, Li Z3, WANG D3
1Beijing Brainpower Pharma Consulting Co. Ltd, Beijing, China, 2China Health Insurance Research 
Association, Beijing, China, 3Boehringer Ingelheim (China) Investment Co., Ltd., Beijing, China
objeCtives: Elderly population is growing and so is the prevalence of diabetes 
among them. The present study was to explore direct medical cost and medication 
usage pattern in hospitalized elderly patients with type 2 diabetes (T2D) among 
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features 64 health states for every combination of study/nonstudy eye, and a health 
state representing death, derived from the VIVID/VISTA-DME and RESTORE/REVEAL 
studies. Economic inputs were based on the experts’ opinions.2 The primary and 
secondary endpoints for the study were life years gained and quality-adjusted life 
years (QALY), and years with 1 eye blind, respectively. Incremental cost-effectiveness 
ratios (ICER) were calculated per QALY and years with 1 eye blind. Analyses were 
conducted from the payer perspective and time horizon was lifetime. All costs were 
calculated in Turkish Lira (TL). Results: Total annual costs associated with IVT-AFL 
and ranibizumab were 15,315 and 14,791 TL, respectively. QALYs were 7.343 with 
IVT-AFL and 7.295 ranibizumab. According to the results of the analysis, IVT-AFL 
is a cost effective treatment option when compared with ranibizumab at a cost-
effectiveness threshold of 26,415 TL (calculated threshold from developing country 
defined as 3-fold of annual income per capita, per the World Health Organization). 
The ICER of IVT-AFL versus ranibizumab was 10,866 TL/QALY. Years with 1 eye blind 
were 0.416 with IVT-AFL and 0.647 with ranibizumab, with a difference of 0.231 year 
in favor of IVT-AFL, giving an ICER of 2268 TL/years with 1 eye blind. ConClusions: 
IVT-AFL may be a cost-effective treatment option when compared with ranibizumab 
for treatment of DME in Turkey.
PDB53
the long-terM cost-effectiveness of twice-Daily exenatiDe with 
insUlin glargine versUs once-Daily liraglUtiDe with insUline 
DeteMir in aDUlt Patients with tyPe 2 DiaBetes in rUssia
Krysanov I1, Tiapkina M2
1Postgraduate Medical Institute, Moscow National University of Food Production, Moscow, Russia, 
2I.M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: to assess the cost-effectiveness of twice daily (TD) 10 μ g exenatide 
with insulin glargine (EXE) vs once-daily (QD) liraglutide 1.2 mg or 1.8 mg both 
with insulin detemir (LIRA 1.2 or LIRA 1.8) in patients with type 2 diabetes mellitus 
(T2DM). Methods: the Exenatide Cost-Effectiveness Model, a validated computer 
simulation model, was adapted to the Russian healthcare setting. Patient and inter-
vention effects data were gathered from a clinical trials (Scott et al 2013, Buse et 
al 2011), comparing QD LIRA 1.2 mg, 1.8 mg and EXE 10 μ g TD, as add-on to insulin 
glargine or detemir. The full costs were calculated for 1-st line therapy, based on 
published and local sources (2014). This includes the costs of drug acquisition as well 
as appropriate inpatient, outpatient and primary care management costs (associ-
ated with maintenance and events). In this study we simulated disease progres-
sion and treatment effects per cohort 1,000 patients for 10 years period. Results: 
over a simulation period, treatment with EXE vs LIRA 1.2 drove a mean increase in 
discounted quality-adjusted life expectancy of 0.1 (0.008; 0.015) quality-adjusted 
life years (QALYs), whereas therapy with EXE vs LIRA 1.8 decrease of 0.1 (-0.018; 
-0.011) QALYs. When compared with LIRA 1.2, EXE was the dominant strategy, i.e. 
less costly (-$484) and more effective. When compared to LIRA 1.8, EXE was less 
costly (-$1,500), but less effective. The incremental cost-effectiveness ratio (ICER) 
for LIRA 1.8 vs EXE was estimated at $100,941 per QALY gained, that more greater 
than willingness-to-pay (WTP) threshold for Russia in 2014 $36,373. In this case 
more cost-effective strategy was EXE with insulin glargine. ConClusions: at a 
WTP threshold of $36,373/QALY exenatide is likely to be a cost-effective option for 
the treatment of T2DM in a Russian setting.
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objeCtives: Key challenges in the adequate management of type 2 diabetes include 
maintaining glycemic control whilst minimizing the risk of hypoglycemia, without 
increasing body weight. Glucagon-like peptide-1 (GLP-1) receptor agonists provide 
a multi-factorial approach to treatment, compared with traditional glucocentric 
approaches. The present analysis aimed to compare the cost-effectiveness of GLP-1 
receptor agonists for the treatment of diabetes in the UK. Methods: Changes in 
glycated hemoglobin, blood pressure and body mass index upon initiation of liraglu-
tide 1.2mg, exenatide BID and lixisenatide were taken from a network meta-analysis 
of 13 randomized controlled trials evaluating the efficacy and safety of GLP-1 recep-
tor agonists for the treatment of patients with type 2 diabetes uncontrolled on oral 
antidiabetic drugs. Patient lifetime projections of clinical outcomes and direct costs 
(taken from published UK-specific sources, 2013 GBP) were made in a cohort based 
on the LEAD-6 trial using a published and validated diabetes model. Outcomes 
were discounted at 3.5% annually. Sensitivity analyses were performed. Results: 
Liraglutide was associated with improved quality-adjusted life expectancy versus 
exenatide (9.17 versus 9.16 quality-adjusted life years [QALYs]) and lixisenatide 
(9.17 versus 9.12 QALYs). Improvements were driven by improved glycemic control, 
leading to a reduced incidence of diabetes-related complications. Liraglutide was 
associated with reduced costs versus exenatide (GBP37,520 versus GBP37,607) with 
cost savings as a result of avoided diabetes-related complications entirely offset-
ting increased acquisition costs. Versus lixisenatide, liraglutide was associated with 
increased costs (GBP37,520 versus GBP37,126), driven by increased acquisition costs 
which were partially offset by reduced costs of treatment of complications. Based 
on the projected outcomes, liraglutide was found to be dominant over exenatide 
and associated with an incremental cost-effectiveness ratio of GBP7,367 per QALY 
gained versus lixisenatide. ConClusions: Liraglutide 1.2mg is likely to be con-
sidered cost-effective or cost-saving versus alternative GLP-1 receptor agonists for 
treatment of diabetes in the UK.
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healthcare costs or all-cause medical costs in either sample. ConClusions: This 
real-world study suggests that short-term weight loss is associated with attain-
ment of HbA1c< 7 levels and decreased diabetes-related costs in obese population 
with no prior CVD over subsequent 12 months.
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objeCtives: Type 2 diabetes mellitus (DM) represents an important public health 
issue and it is responsible for a significant epidemiologic and economic burden. A 
cost consequence analysis (CN), aimed at assessing the economic impact of sitaglip-
tin (SITA), compared with sulfonylureas –SU (as second line therapy- add on to met-
formin) was peformed on the basis of the value based pricing approach. Methods: 
A CN of SITA vs SU (glibenclamide5mg) was carried out, on a cohort of 1000 diabetic 
patients, from both the Lombardy Regional Health Service (RHS) and societal per-
spectives by considering 12 and 36 months time horizons. Direct (drug, automonitor-
ing glycemic control, visits, hypoglicaemic- HYPOS- and CV events, and durability 
costs) and indirect costs have been considered. Epidemiologic and effectiveness 
data have been collected through available literature, trials and meta-analyses. 
Economic data have been retrieved through local/regional sources, tariffs and 
from available literature. Results: The CN analysis shows that SITA+metformin 
vs glibenclamide+metformin represents a cost saving alternative, over 3 years 
time horizon, as higher drug costs of SITA are offset by : - lower glycemic control, 
complications and durability costs resulting in a saving of almost € 9.000 from RHS 
perspective - lower productivity loss related to major cardiovascular and to HYPOS, 
leading to a saving of about € 100.000 from societal perspective. Also, SITA vs SU 
would provide, from both perspectives, -236 not severe and -54 severe HYPOS and 
-14 CV events. The analysis performed over 12 months time horizon shows that 
SITA+metformin represents a sustainable alternative from both RHS and societal 
perspectives, by leading to a saving in terms of HYPOS 136 (118 not severe and 18 
severe) and 7 CV events. ConClusions: The analysis performed shows that SITA 
represents a sustainable and cost saving alternative for the management of type 2 
DM from both clinical and economic perspectives in Lombardy.
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objeCtives: Exenatide 2mg once-weekly (EQW) is a glucagon-like peptide-1 
receptor agonist (GLP-1 RA). The objective was to assess the cost-effectiveness 
of EQW compared to the GLP-1 RAs dulaglutide 1.5mg QW, liraglutide 1.2mg 
and 1.8mg once-daily (QD), and lixisenatide 20ug QD for the treatment of adult 
patients with type 2 diabetes mellitus (T2DM) not adequately controlled on met-
formin. Methods: This analysis utilized the Cardiff Model, a previously pub-
lished T2DM disease model. Treatment effects were from a network-meta-analysis. 
Quality-adjusted life years (QALYs) were calculated, with health-state utilities 
applied to weight changes, hypoglycemia, and T2DM-related complications. Costs 
(British pounds, £) included medication and T2DM-related complications. The 
model was run over a 40-year time horizon. Costs and QALYs were discounted at 
3.5% annually. Probabilistic sensitivity analysis (PSA) was performed. Results: 
In all comparisons, EQW was associated with a QALY gain per patient; 0.046 (95% 
confidence interval [CI]: 0.036; 0.056) versus dulaglutide 1.5mg; 0.102 (95% CI: 0.093; 
0.112) versus liraglutide 1.2mg; 0.043 (95% CI: 0.034; 0.053) versus liraglutide 1.8mg; 
and 0.074 (95% CI: 0.064; 0.083) versus lixisenatide 20ug. Cost per patient was lower 
for EQW than for dulaglutide 1.5mg (-£885; 95% CI: -£942; -£827) and liraglutide 
1.8mg (-£2,085; 95% CI: -£2,143; -£2,028). EQW was therefore projected to dominate 
(i.e, lower costs and QALYs gained) dulaglutide 1.5mg and liraglutide 1.8mg. The 
cost difference per patient between EQW and liraglutide 1.2mg and EQW and 
lixisenatide 20ug was £103 (95% CI: £46; £160) and £918 (95% CI: £861; £975), respec-
tively. Cost per QALY gained with EQW versus liraglutide 1.2mg and lixisenatide 
20ug was £1,004 and £12,440, respectively. In the PSA, the probability that EQW 
is cost-effective ranged from 76-99% across all comparisons, at a willingness-to-
pay threshold of £20,000 per QALY gained. ConClusions: Results suggest that 
exenatide 2mg once-weekly is a cost-effective therapeutic option for the treatment 
of T2DM in adults inadequately controlled on metformin alone.
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objeCtives: IVT-AFL is indicated for the treatment of visual impairment due to 
DME. The objective of this analysis was to evaluate the CE of IVT-AFL compared with 
ranibizumab in DME in Turkey. Methods: The CE model is a Markov state transi-
tion model that has 3 separate phases (efficacy, maintenance, rest of life) chosen to 
adequately reflect the typical vision changes in a treated DME patient. The model 
